ArticleCureus2026
Progressive Multifocal Leukoencephalopathy: A Rare Cause of Altered Mentation.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating neurologic disease caused by the John Cunningham virus (JCV). Most affected patients have human immunodeficiency virus (HIV), but medications are also a risk factor. It can be difficult to diagnose PML as it can present with a broad range of symptoms, especially if other conditions are present that also contribute to encephalopathy. We report a case of a patient who developed PML from medications rarely associated with PML in the setting of multiple comorbid medical conditions that contributed to diagnostic delay. A 63-year-old female patient presented with subacute, intermittent encephalopathy, weakness, and dysphagia. She had a known history of cirrhosis, Sjogren's syndrome, and sarcoidosis, for which she was on chronic azathioprine and prednisone. Initial workup showed laboratory and exam findings consistent with hepatic encephalopathy (HE) and cystitis. Despite appropriate treatment, her condition worsened, and magnetic resonance imaging found confluent white matter lesions throughout her brain. Lumbar puncture was positive for JCV DNA, and she passed away soon after diagnosis. Only one other case report of a patient developing PML while taking both azathioprine and prednisone for sarcoidosis exists. Patients with PML commonly experience cognitive disturbances, which can mimic more common disease processes, such as HE and infections. Our patient presented with these comorbid conditions, which delayed diagnosis. There are no established treatment options for PML patients without HIV except withdrawal of the offending medications. Clinicians must maintain awareness to diagnose PML as it has a broad presentation pattern, and comorbid conditions can further complicate diagnosis. Patients should be maintained on the minimally effective dose of immunosuppression to reduce the risk of PML development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.